Oral escitalopram ( DrugBank: Escitalopram )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00070941 (ClinicalTrials.gov) | July 2003 | 9/10/2003 | SAM-e for the Treatment of Depression in Patients With Parkinson's Disease | SAM-e Treatment of Depression in Parkinson's Disease. | Parkinson's Disease;Depression | Drug: SAM-e;Drug: oral escitalopram;Drug: placebo | New York University School of Medicine | National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS) | Completed | 30 Years | 80 Years | All | 29 | Phase 2/Phase 3 | United States |